Skip to content
Search
Please enter at least 3 characters.

Latest Stories

TECHNOLOGY: Digital transformation in pharmacy

In order to meet the challenges facing a post pandemic NHS, the digital transformation agenda needs to adapt and accelerate even faster, writes Chris Barker…

Throughout the past decade, digital transformation has been at the forefront of the agenda for the NHS which has been accelerated by the abundance of digitally enabled ways of working during the pandemic. While the last year has unquestionably heralded the spring shoots of transformation, there is so much to be done to build upon this and accelerate further.


For example, do both pharmacists and patients comprehend the value of digital to drive change at a fundamental level? The issue is not simply ensuring that the temporary fixes inspired by the pandemic successfully transition to standard practice, but also rapidly building on that foundation to enable the greatest value from digitisation within pharmacy.

Covid-19 has increased the need for digitally enabled and empowered ways of operating. From the backlog in outpatient appointments to postponed screening programmes and, crucially, the potential exodus of overworked and stressed pharmacists, the efficient, effective and intelligent care enabled by the right digital technologies is now critical.

Digital confidence

Wider digital confidence in both patients and pharmacists has supported many of the remarkable transformations in the way pharmacy processes have been delivered over the past year.

There is huge momentum-certainly at a national level – to use digital technologies to transform the way patient services are delivered; to build on the adoption of telemedicine and federated service delivery – for example with Covid vaccination clinics – to drive further change. But this is not new. From the Long Term Plan to the establishment of Integrated Care Systems (ICS), the use of digital technologies to provide joined up, patient centric care across both health and community services is securely embedded on the NHS agenda.

The challenges presented by Covid -19 enabled organisations to bypass some of the legacy constraints related to delivering IT projects across the NHS. Yet the success of many of the temporary solutions, albeit digitally enabled, were as much down to the incredible drive and resilience of individuals as any technology. Progress has been made – but in truth, the changes made in digital transformation within the NHS to date is only the beginning of the journey.

Encouraging digital change

As the NHS presses on with digital plans, which are vital to support the short-term restoration and recovery of critical services post-pandemic, it is important to learn from the past year, reinforce new digital confidence and prevent losing the innovations that have been achieved. This is about protecting the NHS against slipping back into past behaviours that undermine the power of digital technologies to positively transform pharmacy operations. It is about addressing health inequalities, governance and workforce issues; and, fundamentally, it is about integration, whole system thinking, clinical practice and innovation.

This will call for significant, consistent change. It will require not only an investment in digital technologies but also a dedication to assist staff at every level with digital skills, with the knowledge and ability to intuitively leverage systems and tools to support new ways of delivering care.

The message must also be correctly framed. We know that remote care services, when supported with instant access to shared care records, are extremely effective – anecdotal evidence suggests that an individual can effectively manage twice as many patients as in a traditional face to face model. But, in a clinical resource depleted NHS, digital technologies must be about so much more than efficiency.

It is now important to show pharmacists what true digital transformation can enable-and that requires a shift away from reactive to proactive healthcare provision.

Remote care

The NHS care model has, by default, been reactive. Digital technology can totally change this approach by reducing the risk to patients and providing both patients and pharmacists with tools that allow more proactive, personalised care.

Healthcare economies are using digital technologies at a local and even a regional level, to increase services through collaboration between primary, community, pharmacy and acute organisations. This offers both physical and virtual joined-up support to help patients better manage their health, and enable real-time, proactive intervention to prevent patient deterioration and exacerbations.

Online pharmacies, for example, are becoming increasingly effective in providing specialist services to help patients control and become educated about their condition, in addition to dispensing prescribed medication. Especially during the Covid-19 pandemic, digitally prescribing medicines has allowed vulnerable patients to stay safe at home.

Unlike a busy high-street pharmacy, an online pharmacy has more scope to offer enhanced services to patients that can be laser-focused on certain conditions. While they dispense medications and can offer advice on all conditions, they do have the flexibility to hone in on certain specialisms due to their virtual nature.

Adding education and advice around disease management, combined with health population analytics enabled by new, exciting technologies such as AI and machine learning, can change the way in which patients think about their overall health. In turn, this helps improve care pathways for specific diseases - providing huge value to all.

Meeting demands

This is not a ten-year digital vision. This is an immediate need and something that a digitally driven NHS should be driving towards now. The technology is available and proven – the barriers are, in the main, culture and perception. Which is why, despite everything changing, nothing has changed – yet. The NHS needs to continue to push forward with education to build confidence in digital technologies and, critically, to sell the benefits.

This is a significant change in working practice – but it is a change that will deliver huge benefits for pharmacists, both in terms of working practices and the patient outcomes. The right digital technologies, in alignment with proactive care and the ability to deliver care through multiple pathways, will remove the tedious burden from clinicians by releasing talented, experienced individuals to maximise their skills with patient centric care.

It will help them to reach more patients, not just by replacing face to face with remote care but through intelligent, information driven care, where patients and pharmacists are empowered by information collected continuously through monitoring tools.

If the NHS gets this next stage of digital transformation correct, it will open the way for more innovation; for new, better ways of keeping patients out of hospital. Digital technologies have the power to change lives - it is the way that aspect of the digital model is presented and deployed to all involved that will be the basis for a health service suitable for the requirements of the 21st century.

Chris Barker is CEO at Spirit Health Group.

More For You

How community pharmacies can safely and profitably deliver high-quality NHS and private services

L-R: Baba Akomolafe, Rachna Chhatralia, Patricia Tigenoah-Ojo, and Raj Matharu

How community pharmacies are optimising services for a sustainable future

“Community pharmacy has come to a point where we have to change ourselves,” said Raj Matharu, CEO at Community Pharmacy South East London, and Superintendent Pharmacist of Westchem Pharmacy, as he opened a panel discussion at the recent Pharmacy Business Conference.

The 'Optimising Service Opportunities' session centred on how community pharmacies can safely and profitably deliver high-quality NHS and private services, while ensuring an excellent patient experience.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Janet Morrison discusses pharmacy funding strategy at 2025 conference

Health Secretary Wes Streeting outlines government support for community pharmacy

CPE calls new funding deal a ‘reluctant yes’

Community Pharmacy England (CPE) was “reluctant” to accept the new pharmacy funding deal due to the significant funding gap, said the organisation’s chief executive Janet Morrison, while recognising the settlement as the first step towards stabilising the sector.

Addressing the 2025 Pharmacy Business Conference on Sunday at London Hilton Wembley, Janet shared insights into the behind-the-scenes work that led to the agreement.

Keep ReadingShow less